Immunomodulatory Agents for Coronavirus Disease-2019 Pneumonia
Copyright © 2022 Elsevier Inc. All rights reserved..
Morbidity and mortality from COVID-19 is due to severe inflammation and end-organ damage caused by a hyperinflammatory response. Multiple immunomodulatory agents to attenuate this response have been studied. Corticosteroids, specifically dexamethasone, have been shown to reduce mortality in hospitalized patients who require supplemental oxygen. Interleukin-6 antagonist, tocilizimab, and Janus kinase inhibitors have also been shown to reduce mortality. However, patients who have severe pulmonary end-organ damage requiring mechanical ventilation or extracorporeal membrane oxygenation appear not to benefit from immunomodulatory therapies. This highlights the importance of appropriate timing to initiate immunomodulatory therapies in the management of severe COVID-19 disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Clinics in chest medicine - 44(2023), 2 vom: 21. Juni, Seite 299-319 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
McManus, Dayna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 25.04.2023 Date Revised 13.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ccm.2022.11.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355889749 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355889749 | ||
| 003 | DE-627 | ||
| 005 | 20240313233417.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ccm.2022.11.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1326.xml |
| 035 | |a (DE-627)NLM355889749 | ||
| 035 | |a (NLM)37085221 | ||
| 035 | |a (PII)S0272-5231(22)00125-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a McManus, Dayna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunomodulatory Agents for Coronavirus Disease-2019 Pneumonia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.04.2023 | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a Morbidity and mortality from COVID-19 is due to severe inflammation and end-organ damage caused by a hyperinflammatory response. Multiple immunomodulatory agents to attenuate this response have been studied. Corticosteroids, specifically dexamethasone, have been shown to reduce mortality in hospitalized patients who require supplemental oxygen. Interleukin-6 antagonist, tocilizimab, and Janus kinase inhibitors have also been shown to reduce mortality. However, patients who have severe pulmonary end-organ damage requiring mechanical ventilation or extracorporeal membrane oxygenation appear not to benefit from immunomodulatory therapies. This highlights the importance of appropriate timing to initiate immunomodulatory therapies in the management of severe COVID-19 disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Corticosteroids | |
| 650 | 4 | |a Immunomodulatory treatment | |
| 650 | 4 | |a JAK inhibitors | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Immunomodulating Agents |2 NLM | |
| 700 | 1 | |a Davis, Matthew W |e verfasserin |4 aut | |
| 700 | 1 | |a Ortiz, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Britto-Leon, Clemente |e verfasserin |4 aut | |
| 700 | 1 | |a Dela Cruz, Charles S |e verfasserin |4 aut | |
| 700 | 1 | |a Topal, Jeffrey E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinics in chest medicine |d 1991 |g 44(2023), 2 vom: 21. Juni, Seite 299-319 |w (DE-627)NLM012973599 |x 1557-8216 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2023 |g number:2 |g day:21 |g month:06 |g pages:299-319 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ccm.2022.11.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2023 |e 2 |b 21 |c 06 |h 299-319 | ||